An overview of Sgc8 aptamer as a potential theranostic agent for cancer with PTK7 oncogenic target.

Abstract

Aptamers have attracted exceptional attention in medical field due to their intrinsic properties equivalent to antibodies such as high target affinity, low immunogenicity and toxicity, cost-effectiveness and ease of synthesis and modification, and good stability under extreme conditions, thereby providing new avenues for basic research and clinical application. Protein tyrosine kinase 7 (PTK7) has been proved to be closely linked with the progression of many types of cancer. The aberrant expression of PTK7 has positioned it as a potential theranostic biomarker for multiple cancers. Aptamer sgc8 was initially identified for its high-affinity binding to PTK7 on the T-cell acute lymphoblastic leukemia cell line (CCRF-CEM) through cell-SELEX (systematic evolution of ligands by exponential enrichment) and subsequently has demonstrated the ability to effectively recognize many types of cancer cells that express PTK7 oncogenic target. The easily modifiable nature of sgc8 facilitates its conjugation with functional agents and drugs. This identification mode and modification approach of aptamers against cancer cells provides a potential strategy for cancer diagnosis and treatment. In this review, we discuss the potential of sgc8 aptamers in early cancer diagnosis and targeted therapy, focusing specifically on their interaction with the oncogenic biomarker PTK7.